336
Views
15
CrossRef citations to date
0
Altmetric
Invited Review

Predicting response to lithium in bipolar disorder: A critical review of pharmacogenetic studies

, &
Pages 142-156 | Published online: 08 Apr 2010

References

  • Benedetti, F., Serretti, A., Pontiggia, A., Bernasconi, A., Lorenzi, C., Colombo, C., Smeraldi, E. (2005). Long-term response to lithium salts in bipolar illness is influenced by the glycogen synthase kinase 3-[beta] -50 T/C SNP. Neuroscience Letters, 376(1), 51–55.
  • Blanco, C., Laje, G., Olfson, M., Marcus, S.C., Pincus, H.A. (2002). Trends in the treatment of bipolar disorder by outpatient psychiatrists. American Journal of Psychiatry, 159(6), 1005–1010.
  • Craddock, N., O'Donovan, M., Owen, M. (2008). Genome-wide association studies in psychiatry: Lessons from early studies of non-psychiatric and psychiatric phenotypes. Molecular Psychiatry, 13(7), 649–653.
  • Goodwin, F.K., Jamison, K.R. (2007). Manic-depressive illness: Bipolar disorders and recurrent depression. New York: Oxford University Press.
  • Green, E.K., Raybould, R., Macgregor, S., Hyde, S., Young, A.H., O'Donovan, M.C., Owen, M.J., Kirov, G., Jones, L., Jones, I., Craddock, N. (2006). Genetic variation of brain-derived neurotrophic factor (BDNF) in bipolar disorder: Case-control study of over 3000 individuals from the UK. British Journal of Psychiatry, 188(1), 21–25.
  • Heils, A., Teufel, A., Petri, S., Stöber, G., Riederer, P., Bengel, D., Lesch, K.P. (1996). Allelic variation of human serotonin transporter gene expression. Journal of Neurochemistry, 66, 2621–2624.
  • Kato, T., Kunugi, H., Nanko, S., Kato, N. (2001). Mitochondrial DNA polymorphisms in bipolar disorder. Journal of Affective Disorders, 62, 151–164.
  • Kleindienst, N., Engel, R.R., Greil, W. (2005a). Which clinical factors predict response to prophylactic lithium? A systematic review for bipolar disorders. Bipolar Disorders, 7(5), 404–417.
  • Kleindienst, N., Engel, R.R., Greil, W. (2005b). Psychosocial and demographic factors associated with response to prophylactic lithium. A systematic review for bipolar disorders. Psychological Medicine, 35, 1685–1694.
  • Lesch, K.P., Heils, A. (2000). Serotonergic gene transcriptional control regions: Target for antidepressant drug development. International Journal of Neuropsychopharmacology, 3, 67–79.
  • Masui, T., Hashimoto, R., Kusumi, I., Suzuki, K., Tanaka, T., Nakagawa, S., Kunugi, H., Koyama, T. (2006). A possible association between the -116C/G single nucleotide polymorphism of the XBP1 gene and lithium prophylaxis in bipolar disorder. Journal of Neuropsychopharmacology, 9, 83–88.
  • Masui, T., Hashimoto, R., Kusumi, I., Suzuki, K., Tanaka, T., Nakagawa, S., Suzuki, T., Iwata, N., Ozaki, N., Kato, T., Kunugi, H., Koyama, T. (2006). Lithium response and Val66Met polymorphism of the brain-derived neurotrophic factor gene in Japanese patients with bipolar disorder. Psychiatric Genetics, 16(2), 49–50.
  • Michelon, L., Meira-Lima, I., Cordeiro, Q., Miguita, K., Breen, G., Collier, D., Vallada, H. (2006). Association study of the INPP1, 5HTT, BDNF, AP-2[beta] and GSK-3[beta] GENE variants and restrospectively scored response to lithium prophylaxis in bipolar disorder. Neuroscience Letters, 403(3), 288–293.
  • NICE (2006). Bipolar disorder: The management of bipolar disorder in adults, children and adolescents, in primary and secondary care. www.nice.org.uk/CG038
  • Rybakowski, J.K., Suwalska, A., Czerski, P.M., Dmitrzak-Weglarz, M., Leszczynskia-Rodziewicz, A., Hauser, J. (2005a). Prophylactic effect of lithium in bipolar affective illness may be related to serotonin transporter genotype. Pharmacological Reports, 57, 124–127.
  • Rybakowski, J.K., Suwalska, A., Skibinska, M., Dmitrzak-Weglarz, M., Leszczynska-Rodziewicz, A., Hauser, J. (2007). Response to lithium prophylaxis: Interaction between serotonin transporter and BDNF genes. American Journal of Medical Genetics Part B (Neuropsychiatric Genetics), 144B, 820–823.
  • Rybakowski, J.K., Suwalska, A., Skibinska, M., Szczepankiewicz, A., Leszczynska-Rodziewicz, A., Permoda, A., Czerski, P.M., Hauser, J. (2005b). Prophylactic lithium response and polymorphism of the brain-derived neurotrophic factor gene. Pharmacopsychiatry, 38(4), 166–170.
  • Serretti, A., Lorenzi, C., Lilli, R., Mandelli, L., Pirovano, A., Smeraldi, E. (2002). Pharmacogenetics of lithium prophylaxis in mood disorders: Analysis of COMT, MAO-A, and Gß3 variants. American Journal of Medical Genetics Part B (Neuropsychiatric Genetics), 144, 370–379.
  • Serretti, A., Lorenzi, C., Lilli, R., Smeraldi, E. (2000). Serotonin receptor 2A, 2C, 1A genes and response to lithium prophylaxis in mood disorders. Journal of Psychiatric Research, 34(2), 89–98.
  • Serretti, A., Lilli, R., Lorenzi, C., Franchini, L., Di Bella, D., Catalano, M., Smeraldi, E. (1999a). Dopamine receptor D2 and D4 genes, GABAA alpha-1 subunit genes and response to lithium prophylaxis in mood disorders. Psychiatry Research, 87, 7–19.
  • Serretti, A., Lilli, R., Lorenzi, C., Franchini, L., Smeraldi, E. (1998). Dopamine receptor D3 gene and response to lithium prophylaxis in mood disorders. International Journal of Neuropsychopharmacology, 1, 125–129.
  • Serretti, A., Lilli, R., Lorenzi, C., Gasperini, M., Smeraldi, E. (1999b). Tryptophan hydroxylase gene and response to lithium prophylaxis in mood disorders. Journal of Psychiatric Research, 33, 371–377.
  • Serretti, A., Lilli, R., Mandelli, L., Lorenzi, C., Smeraldi, E. (2001). Serotonin transporter gene associated with lithium prophylaxis in mood disorders. The Pharmacogenomics Journal, 1, 71–77.
  • Sklar, P., Gabriel, S.B., McInnes, M.G., Bennett, P., Lim, Y.M., Tsan, G., Scaffner, S., Kirov, G., Jones, I., Owen, M., Craddock, N., Depaulo, J.R., Lander, E.S. (2002). Family-based association study of 76 candidate genes in bipolar disorder: BDNF as a potential risk locus. Molecular Psychiatry, 7, 579–593.
  • Smith, L.A., Cornelius, V., Warnock, A., Bell, A., Young, A.H. (2007). Effectiveness of mood stabilizers and antipsychotics in the maintenance phase of bipolar disorder: A systematic review of randomized controlled trials. Bipolar Disorders, 9(4), 394–412.
  • Steen, V.M., Løvlie, R., Osher, Y., Belmaker, R.H., Berle, J.Ø., Gulbrandsen, A.K. (1998). The polymorphic inositol polyphosphate 1-phosphatase gene as a candidate for pharmacogenetic prediction of lithium-responsive manic-depressive illness. Pharmacogenetics, 8, 259–268.
  • Washizuka, S., Ikeda, A., Kato, N., Kato, T. (2003). Possible relationship between mitochondrial DNA polymorphisms and lithium response in bipolar disorder. International Journal of Neuropsychopharmacology, 6, 421–424.
  • WTCCC (Wellcome Trust Case Control Consortium) (2007). Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature, 447(7145), 661–678.
  • Young, A.H., Hammond, J.M. (2007). Lithium in mood disorders: Increasing evidence base, declining use? British Journal of Psychiatry, 191(6), 474–476.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.